metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
ovarian cancer (OC) ovarian cancer (OC)
versus Standard of Care (SoC)
	olaparib
	SOLO 3, 2020 J Clin Oncol 2020 Apr 10;38(11):1164-1174. NCT02282020	RCT	ovarian cancer (OC)	olaparib 300 mg twice a day	SOC	patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer who had received at least 2 prior lines of platinum-based chemotherapy	178 / 88	NA	safety concern	safety concern with 7 % increase in deaths (OS) (not statistically significant) suggested 38 % decrease in PFS (extension)
	PAOLA-1/ENGOT-ov25, 2019 N Engl J Med 2019 Dec 19;381(25):2416-2428. Eur J Cancer 2022 Oct;174:221-231. NCT02477644	RCT	ovarian cancer (OC)	olaparib plus bevacizumab	placebo plus bevacizumab	patents with newly diagnosed, advanced, high-grade ovarian cancer and were having a response after first-line platinum-taxane chemotherapy plus bevacizumab	537 / 269	NA	suggested	suggested 41 % decrease in PFS (extension)
	SOLO 1, 2018 N. Engl. J. Med. 2018; 379:2495-2505 Lancet Oncol 2021 Dec;22(12):1721-1731. NCT01844986	RCT	ovarian cancer (OC)	olaparib tablets (300 mg twice daily)	placebo	Newly Diagnosed Advanced Ovarian Cancer with a mutation in BRCA1, BRCA2, or both ( BRCA1/2) who had a complete or partial clinical response after platinum-based chemotherapy	260 / 131	NA	suggested	suggested 45 % decrease in deaths (OS) suggested 70 % decrease in progression or deaths (PFS)
	SOLO2/ENGOT-Ov21, 2018 Lancet Oncol 2017;: Lancet Oncol. 2018; 19:1126-1134 Lancet Oncol 2021 May;22(5):620-631. NCT01874353	RCT	ovarian cancer (OC)	olaparib 300 mg in two 150 mg tablets, twice daily	placebo	patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation	196 / 99	NA	suggested	suggested 70 % decrease in progression or deaths (PFS)
	Ledermann, 2012 N Engl J Med 2012;366:1382-92 Lancet Oncol. 2016; 17:1579-1589 Cancer 2016; 122:1844-52 Lancet Oncol. 2014; 15:852-61 Br. J. Cancer 2016; 115:1313-1320 NCT00753545	RCT	ovarian cancer (OC)	olaparib, at a dose of 400 mg twice daily	placebo	maintenance therapy in platinum-sensitive relapsed ovarian cancer	136 / 129	NA	suggested	suggested 65 % decrease in PFS (extension)

ovarian cancer (OC) ovarian cancer (OC)

versus Standard of Care (SoC)

olaparib